THE INVENTION RELATES TO METHODS FOR PRODUCING CHALCONE (1,3-DIPHENYLPROP-2-EN-1 -ONE) DERIVATIVES THAT HAVE MULTIPLE SUBSTITUTIONS ON A PHENYL RING. INTERMEDIATE CHALCONE DERIVATIVES ARE MODIFIED BY PHASE TRANSFER CATALYSIS (PTC) FOR INTRODUCING A SUBSTITUTED ALKYL GROUP THAT IS PROVIDED BY A SULFONIC ACID DERIVATI...

The present invention relates to compounds derived from substituted 3-phenyl-1-(thien-2-yl)propan-1-ones, pharmaceutical compositions comprising them as well as their therapeutic applications, notably in the field of human and animal health .

The present invention provides novel 6 substituted [1 2 4]triazolo[4 3 b]pyridazines that are agonists of Rev Erb. These compounds and pharmaceutical compositions comprising the same are suitable means for treating any disease wherein the activation of Rev Erb has therapeutic effects for instance in inflammatory and...

The present invention relates to novel 1 3 diphenylpropane derivatives pharmaceutical compositions comprising the same and therapeutic uses thereof in particular in the fields of human and animal health. The compounds according to the present invention have intrinsic PPAR agonist properties. They are therefore of pa...

The present invention relates to the use of compound l-[4-methylthiophenyl]-3-[3,5- dimethyl-4-carboxydimethylmethyloxyphenyl] prop-2-en-l-one for treating fibrotic diseases and cancers.

The invention relates to a method for the preparation of 1,3-diphenylprop-2-en-1-one derivatives substituted on one of the two phenyl groups by a carboxyalkyloxy group or a carboxyalkylthio group.

Acylated aminopropanediol compounds and nitrogen and sulfur analogues thereoof represented by general formula (I): in which G2 and G3 independently represent an oxygen atom, a sulfur atom or a N-R4 group, wherein G2 and G3 do not simultaneously represent a N-R4 group, R and R4 independently represent a hydrogen ato...

The invention concerns novel substituted l,3-diphenylprop-2-en-l-one derivatives, pharmaceutical compositions comprising same, their therapeutic uses, in particular for treating cerebral ischemia. The invention also concerns a method for preparing said derivatives.

The invention concerns compositions comprising substituted l,3-diphenylprop-2-en-l-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, canc...

The present invention relates to substituted 1,3-diphenylpropane derivatives, to the pharmaceutical compositions containing them and to the therapeutic uses thereof, in particular in the fields of human and animal health.

The present invention relates to substituted 1,3-diphenylpropane derivatives, to the pharmaceutical compositions containing them and to the therapeutic uses thereof, in particular in the fields of human and animal health.

The invention relates to a method for the diagnosis of non alcoholic steatohepatitis (NASH) for determining the activity the stage or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other bood circulating markers of liver d...

The invention relates to substituted 1,3-diphenylprop-2-en-1-one derivative compounds, pharmaceutical and/or cosmetic compositions containing same, and the applications thereof in therapeutics and cosmetics. The invention also relates to a method for preparing said derivatives.

The present invention relates to polysubstituted imidazolone derivatives, having PPAR activating properties and ATI receptor antagonist properties, to the pharmaceutical compositions containing them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a pro...

The invention provides 1 3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders  in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1 3-diphenylprop-2-en-1-one derivatives of General Formula...

The present invention relates to a synergistic combination of active ingredients for use in the treatment of fibrotic diseases.

The invention relates to methods for producing chalcone (1,3-diphenylprop-2-en-1 -one) derivatives that have multiple substitutions on a phenyl ring. Intermediate chalcone derivatives are modified by Phase Transfer Catalysis (PTC) for introducing a substituted alkyl group that is provided by a sulfonic acid derivati...

The present invention relates to a combination of active ingredients for use in the treatment of diseases.

The present invention relates to a combination of active ingredients for use in the treatment of diseases.

The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related disease...

The present invention provides e.g. N-{[2-(piperidin-1-yl)phenyl] (phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic dis...

The present invention relates to a combination product and its use in therapy.

The present invention relates to a combination product and its use in therapy.

The present invention relates to a combination product and its use in therapy.

The present invention relates to a non-invasive method for the diagnosis of a non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, and/ or liver fibrosis, based on the level of miR-452 in a body fluid sample.

The present invention relates to the stabilization of micro-RNA molecules. The compositions and methods described herein can advantageously be used for the provision of internal control and standard microRNAs for inclusion into kits, useful for the normalized, relative or absolute quantification of a microRNA in a b...

The present invention relates to novel crystalline forms of elafibranor.

The invention relates to a novel method for the diagnosis of non-alcoholic steatohepatitis (NASH) and for classifying a subject as a potential receiver of a treatment for NASH.

The present invention relates to a combination product and its use in therapy.

The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune...

The present invention relates to a novel non-invasive method for the diagnosis of a non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, and/or liver fibrosis.

The present invention relates to a novel automated pattern recognition and scoring method of histological images.

The present invention is directed to novel compositions and methods useful for the quantitative detection of microRNAs. More particularly, it relates to premixes useful in reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) reactions for the detection of miR-34.

The present invention provides improved methods for the diagnosis of at-risk NASH.

Provided herein is a method of diagnosing or prognosing advanced liver fibrosis or liver cirrhosis in a patient. The method is accomplished by determining a score based on the circulating levels in serum of three markers.

Provided herein is a method of diagnosing or prognosing advanced liver fibrosis or liver cirrhosis in a patient. The method is accomplished by determining a score based on the circulating levels in serum of two markers.

The present invention relates to a new assay to diagnose nonalcoholic steatohepatitis (NASH), NASH progression and NASH fibrosis stage.

The invention relates to a combination of substituted 2,4 diamino-quinoline compounds and MEK inhibitors, pharmaceutical compositions containing it and its use as a medicament. The invention further relates to a combination of substituted 2,4 diamino-quinoline compounds and MEK inhibitors, for use in the prevention ...

The present invention relates to formulations of elafibranor or a pharmaceutically acceptable salt or ester thereof; and uses thereof. In particular, the present invention relates to an oral solid dosage form comprising at least elafibranor or a pharmaceutically acceptable salt or ester thereof; a filler, a disinteg...